Just a Few Medical Visits Reshaped Indigenous Amazonians’ Gut Microbiome, Study Finds

Four months. That is all it took for the gut microbiomes of remote Amazonian Indigenous communities to begin shifting toward the depleted, less-diverse patterns typical of industrialized populations. A new study published in Cell Reports by Maria G. Dominguez-Bello of Rutgers University and an international team reveals that even minimal exposure to modern medicine, in this case routine antiparasitic treatment, can rapidly restructure the microbial communities inside the human gut, mouth, and skin.

Gut Microbial Diversity Collapsed After Antiparasitic Treatment

The remote Venezuelan Amazonian villages at the center of this study are among the least medically exposed communities on Earth. Their inhabitants maintain traditional diets and lifestyles with minimal urban contact, and before treatment began, their gut microbiomes reflected that isolation: microbial diversity was significantly higher than that seen in Amazonian communities with more urban contact, a finding consistent with earlier work on Yanomami gut microbiome diversity that documented the most diverse bacterial collections ever found in humans. Research on ancestral microbiome patterns from ancient paleofeces similarly suggests that pre-industrial humans harbored a richer microbial ecology than people alive today.

That baseline diversity began eroding quickly once medical visits started. Populations of Prevotella and Treponema, two bacterial genera associated with fiber digestion, diminished in the gut. Bacterial groups common in urban populations, including Bacteroidota and Verrucomicrobia, increased. The shifts were more pronounced in children. Oral and skin microbiota diversity also declined. Nasal microbiota moved in the opposite direction, increasing in diversity after the first visit, though the researchers could not fully explain why gut and nasal sites responded differently.

What This Means for Long-Term Health in Affected Communities

Microbial diversity is not an abstract metric. Research on gut dysbiosis and chronic diseases links imbalances in the gut microbiota to increased inflammation, impaired immune function, and metabolic disturbances, with downstream connections to conditions including obesity, inflammatory bowel disease, allergies, and certain cancers. A broader literature review on microbiota and chronic illness reinforces that the gut microbial community is deeply involved in the pathophysiology of neurological, cardiovascular, and immunological disorders.

For Indigenous Amazonian communities, the implications are layered. These populations are not facing the full suite of Western lifestyle factors, such as processed food diets, antibiotic overuse, or chronic stress, that typically drive microbiome depletion. Yet the microbiome shifts observed here resemble urbanization effects, suggesting that medicine alone, even in small doses, carries enough biological force to remodel microbial ecology. The children in the study showed the sharpest changes, which raises questions about developmental windows when the gut microbiome is most vulnerable to disruption.

How a WHO Onchocerciasis Program Became a Natural Experiment

The study enrolled 335 Indigenous participants across remote villages in the Venezuelan Amazon. Microbiome samples were collected from four body sites, gut, mouth, nose, and skin, during quarterly medical visits in October 2015 and February 2016. Those visits were part of a World Health Organization-supported program to treat and prevent onchocerciasis, commonly known as river blindness, using routine antiparasitic medication alongside basic health services.

As Dominguez-Bello noted, the program offered a rare natural experiment. Because diet, environment, and lifestyle remained essentially unchanged between sampling periods, the researchers could attribute microbiome shifts to medical exposure rather than the confounding factors that complicate most urbanization studies. The team also performed functional metagenomic analysis, looking beyond which bacteria were present to ask what those bacteria were doing. Microbial genes involved in breaking down simple carbohydrates and developing antimicrobial resistance became more common; genes linked to fiber fermentation declined. The drugs appear to be selecting for microbes with different metabolic capabilities and resistance profiles.

Open Questions About Body-Site Differences and Causality

The study is observational. The authors do not claim that modern medicine is overall harmful, and treating river blindness in communities where it causes blindness is an unambiguous good. What the findings do flag is that medicine carries microbial side effects that current public health frameworks rarely account for.

The directional inconsistency across body sites remains unexplained. Gut, oral, and skin diversity fell while nasal diversity rose, and the team acknowledges they cannot yet account for why the nasal microbiome responded differently. Research on long-term medication effects on the gut microbiome from other cohorts has found that nearly half of 186 tested drugs produced changes persisting for years after treatment ended, suggesting the timeline of concern extends well beyond the four-month window captured here. Whether the shifts seen in these Amazonian communities are reversible, or whether they become self-sustaining, is not yet known.

Restoring Microbiota After Medicine and What Comes Next

Dominguez-Bello frames the study as a starting point rather than a verdict. "It opens the door for future research on how we can restore our microbiota after using medicines like antibiotics, which can deplete organisms in our gut," she said. The findings argue for developing public health strategies that preserve the benefits of treatment while limiting unnecessary microbial disruption, whether through probiotic co-administration, targeted drug delivery, or narrower-spectrum formulations.

The sensitivity of the human gut microbiome to even brief medical exposure raises a practical question for global health programs operating in remote or Indigenous communities: if routine treatment reshapes the microbiome in four months, what happens after years of expanding healthcare access? Answering that question will require longitudinal follow-up in the same communities and, as broader microbiome research matures, more sophisticated tools for tracking functional microbial changes at scale.